Landmark Clinical Trials Shaping Patient Care

The Neurology Podcast previews the 2026 AAN Annual Meeting's Clinical Trials Plenary Session, a cornerstone event where landmark neurologic trials are presented directly by their investigators. Hosts H.E. Hinson and Vijay Ramanan, both members of the American Academy of Neurology Science Committee, emphasize that the session is curated for broad impact across neurology subspecialties—prioritizing phase III trials with near-term clinical implications, even in rare diseases. They highlight the unique anticipation surrounding the plenary, where results can reshape practice, confirm or challenge long-held assumptions, and inspire new trial methodologies like platform trials. The episode spotlights several key studies: the ICAP trial testing optimal cooling duration after cardiac arrest using an adaptive design, the Essential 3 study on a calcium channel modulator for essential tremor with innovative decentralized and withdrawal designs, and a pivotal trial of Zalganserin, an RNA-targeted antisense therapy for Alexander disease—a rare, untreatable condition. These trials exemplify how the plenary not only delivers breakthrough results but also advances the science of trial design itself. Beyond the specific findings, the hosts stress that the session’s value extends to all neurologists—whether in community practice or research—by offering early insight into emerging therapies, enabling proactive planning in clinical and administrative roles.